Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Bank of America Corp DE

Bank of America Corp DE lowered its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,775,772 shares of the medical equipment provider's stock after selling 402,266 shares during the period. Bank of America Corp DE owned approximately 1.23% of Hologic worth $200,105,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Venturi Wealth Management LLC increased its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. Smithfield Trust Co boosted its holdings in Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. Finally, Sound Income Strategies LLC acquired a new stake in Hologic during the 4th quarter valued at approximately $60,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.88% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Citigroup reduced their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Royal Bank of Canada cut their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Evercore ISI decreased their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $78.58.

Hologic Stock Performance

HOLX stock traded up $0.56 during mid-day trading on Friday, reaching $56.74. The company had a trading volume of 3,258,934 shares, compared to its average volume of 2,092,764. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The stock has a market capitalization of $12.73 billion, a P/E ratio of 17.90, a P/E/G ratio of 2.14 and a beta of 0.54. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock's 50-day simple moving average is $59.43 and its two-hundred day simple moving average is $68.17.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm posted $1.03 EPS. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.